BioCentury
ARTICLE | Finance

Blend goes platinum

Blend meets VC tests for unique MOA, delivery of platinum-based cancer drugs

December 24, 2012 8:00 AM UTC

Blend Therapeutics Inc. will use last week's $16 million series B round to take one cancer program to an IND and a second to IND-enabling studies.

The lead programs include a "monofunctional" platinum-based molecule and another platinum-based compound...